BiomX (PHGE) AI Stock Analysis

• Market Cap: $8.73M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: N/A
• EPS Growth: 54.25%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.51
• Shares Outstanding: 1,526,640
• 10 Day Avg. Volume: 1,108,900
• 30 Day Avg. Volume: 1,322,820
• PEG Ratio: 0.04
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.38
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -25.37
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $26.00
• Price Target Upside: 354.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $5.50 ▼(-3.85% Downside)

The score is primarily constrained by weak financial performance (no meaningful revenue, continued losses, and heavy cash burn with short runway), with additional pressure from dilution/strategic-risk corporate events. Technical momentum is currently strong but looks overextended, while valuation provides limited support due to losses and no dividend.

Positive Factors

Proprietary phage engineering platform

BiomX’s platform targeting harmful bacteria via engineered bacteriophages is a structural competitive asset. A validated discovery/engineering engine can generate multiple candidates across indications, enabling pipeline breadth, repeatable R&D outputs and long-term licensing or partnership opportunities.

Regulatory clarity for BX011

Clear FDA feedback and a defined pathway toward a Biologics License Application materially reduce development uncertainty for BX011. This long-term regulatory clarity improves the likelihood of eventual approval, supports strategic planning, and enhances the asset’s partnering and commercialization potential.

Improved leverage and positive equity

Leverage materially eased from prior extreme levels to a moderate debt-to-equity ratio, and TTM equity is positive. A less stressed capital structure reduces near-term insolvency risk, preserves strategic optionality for collaborations or financings, and supports continued program investment.

Negative Factors

No commercial revenue; sizable losses

BiomX remains a pre-revenue clinical-stage biotech with substantial recurring net losses. Over the medium term this structural lack of commercial cash flow forces continual reliance on external capital, increasing dilution risk and constraining sustainable investment in multiple late-stage programs.

Severe cash burn and near-term runway risk

With cash only expected to fund operations into Q1 2026, the company faces a structural financing cliff. Persistent negative operating and free cash flow mean recurrent capital raises are likely, which can dilute shareholders, delay trials, or force asset sales, undermining long-term execution.

Program disruption and insolvency filing

Halting a Phase 2b trial and initiating insolvency proceedings for a subsidiary signal material execution and resource-allocation failures. These events reduce pipeline diversification, may impair partnerships, and indicate structural operational and financing weaknesses that can hinder long-term clinical progress.

BiomX Business Overview & Revenue Model

Company Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

How the Company Makes Money

BiomX primarily makes money through research and development collaborations, grants, and potential future product sales. The company engages in partnerships with pharmaceutical and biotechnology companies to co-develop phage therapies, which can provide upfront payments, milestone payments, and royalties. Additionally, BiomX may receive funding from governmental or non-profit grants to support its research initiatives. As its products progress through clinical trials and potentially reach the market, revenue from sales of approved therapies will become a significant source of income.

BiomX Financial Statement Overview

Summary

Development-stage profile with essentially no revenue and sizeable ongoing losses (TTM net loss ~$37.4M) plus persistent cash burn (TTM FCF ~$-28.3M). Balance sheet leverage improved meaningfully versus 2023 (debt-to-equity ~0.63x TTM) and equity remains positive, but continued losses and burn create material funding/dilution risk.

Income Statement

Across annual periods and the latest TTM (Trailing-Twelve-Months), the company reports essentially no revenue, while losses remain sizeable (TTM net loss of ~$37.4M). Profitability is consistently weak with negative gross profit and deeply negative operating results, and there is no visible revenue trajectory to offset ongoing R&D and operating spend. A modest positive is that annual net losses have fluctuated (not strictly worsening every year), but the overall earnings profile remains firmly loss-making.

Balance Sheet

Leverage has improved materially versus 2023, when debt was very high relative to equity (debt-to-equity ~4.9x), to a more moderate level in the latest TTM (Trailing-Twelve-Months) (~0.63x). Equity remains positive (TTM ~$10.5M), supporting balance sheet stability, but profitability remains a key pressure point as returns on equity are strongly negative (TTM roughly -191%). Overall, the capital structure looks less stressed than in prior years, yet ongoing losses could erode equity over time.

Cash Flow

Cash generation is weak, with consistently negative operating cash flow and free cash flow (TTM operating cash flow ~$-28.3M; TTM free cash flow ~$-28.3M). Free cash flow deterioration is notable in the latest TTM (Trailing-Twelve-Months) period, indicating increased cash burn versus the prior year. A relative positive is that cash flow broadly tracks the net loss (free cash flow to net income near 1x), suggesting losses are not being heavily flattered by non-cash items—but the scale and persistence of burn remain the central risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-292.00K	-1.80M	-871.00K	0.00	0.00	0.00
EBITDA	-29.88M	-13.13M	-22.82M	-23.66M	-32.90M	-29.60M
Net Income	-37.38M	-17.73M	-26.17M	-28.32M	-36.23M	-30.09M
Balance Sheet
Total Assets	26.17M	43.23M	25.03M	45.53M	77.99M	70.36M
Cash, Cash Equivalents and Short-Term Investments	7.91M	17.81M	14.91M	33.33M	62.10M	56.33M
Total Debt	6.58M	9.58M	15.09M	19.36M	20.02M	5.89M
Total Liabilities	15.68M	19.09M	21.95M	24.49M	30.45M	12.89M
Stockholders Equity	10.49M	24.15M	3.08M	21.04M	47.53M	57.47M
Cash Flow
Free Cash Flow	-28.31M	-37.01M	-21.34M	-29.20M	-31.25M	-25.46M
Operating Cash Flow	-28.29M	-36.98M	-21.29M	-29.09M	-27.57M	-24.45M
Investing Cash Flow	106.00K	715.00K	1.95M	-2.11M	16.17M	-10.86M
Financing Cash Flow	11.54M	38.37M	2.90M	292.00K	37.28M	134.00K

BiomX Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.72
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHGE, the sentiment is Positive. The current price of 5.72 is above the 20-day moving average (MA) of 3.68, above the 50-day MA of 3.41, and below the 200-day MA of 7.99, indicating a neutral trend. The MACD of 0.88 indicates Negative momentum. The RSI at 67.49 is Neutral, neither overbought nor oversold. The STOCH value of 63.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHGE.

BiomX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LPCN	54 Neutral	$49.97M	-8.87	-32.92%	―	-44.31%	-34.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHGE	47 Neutral	$8.73M	-0.20	-154.50%	―	―	54.25%
CANF	41 Neutral	$5.68M	―	―	―	―	―
IMRN	38 Underperform	$7.97M	-1.54	-49.00%	―	47.17%	26.84%

BiomX Corporate Events

BiomX Completes Private Placement and Board Expansion

On January 13, 2026, the company completed a previously announced private placement of its securities under a Securities Purchase Agreement dated December 26, 2025, and in connection with that closing expanded its board to nine members and appointed investment professional Reuven Yeganeh as an independent Class 1 director, with a term running until the 2027 annual meeting, subject to certain ownership conditions. Also on January 13, 2026, the company entered into a standard-form indemnification agreement with Yeganeh and filed a Certificate of Designations in Delaware establishing its Series Y Convertible Preferred Stock, issuing 3,300 preferred shares alongside warrants for common stock, a move that refines its capital structure and adds experienced financial oversight at the board level.

The most recent analyst rating on (PHGE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Subsidiary Terminates Maryland Facility Lease Agreement

On December 31, 2025, Adaptive Phage Therapeutics, LLC (APT), a wholly owned subsidiary of the Company, entered into a Seventh Amendment to its lease for premises in Gaithersburg, Maryland, resulting in the termination of the lease effective the same date. Under the settlement, APT agreed to a one-time payment of $800,000 and acknowledged the landlord’s draw on an existing letter of credit for $153,557.68, with the landlord agreeing, upon satisfaction of specified conditions, to release APT and the parent company from further obligations and liabilities under the lease, aside from limited surviving obligations, thereby resolving outstanding lease-related claims and closing out the company’s commitments at that facility.

The most recent analyst rating on (PHGE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Announces New Preferred Stock Financing and Warrants

On December 26, 2025, BiomX Inc. entered into a Securities Purchase Agreement with a single investor for a private placement of 3,300 shares of newly created Series Y Convertible Preferred Stock, with an aggregate stated value of $3.3 million, and accompanying warrants to purchase 3,300,000 shares of common stock, for expected gross proceeds of $3.0 million before fees. The Series Y Preferred Stock carries a 15% annual dividend payable in cash or stock, ranks senior to common stock and existing Series X preferred stock, has a one-year maturity, and is initially convertible at $2.00 per share, while the warrants are immediately exercisable at $2.00 per share for five years, with both instruments subject to price adjustments and a 19.99% beneficial ownership cap until stockholder approval is obtained. As part of the deal, the investor secured board representation rights tied to ownership thresholds, BiomX committed to seek stockholder approval within 60 days to permit issuance of more than 19.99% of its outstanding common shares, and it granted registration rights for resale of the underlying securities, signaling a significant equity financing that could meaningfully dilute existing shareholders but strengthens the company’s balance sheet and brings in an influential strategic investor; H.C. Wainwright & Co. acted as exclusive placement agent and will receive fees and additional warrants, and the transaction is expected to close on or about December 30, 2025, subject to customary conditions.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Discontinues Study and Files for Insolvency

On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b study due to resource constraints, which led to the decision to file for insolvency proceedings for its Israeli subsidiary, BiomX Ltd. The company is now evaluating strategic options while maintaining its BX011 program for diabetic foot infections.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Discontinues Phase 2b Trial for BX004

On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b clinical trial for BX004, a treatment for Cystic Fibrosis associated with chronic Pseudomonas aeruginosa infections, due to resource constraints. The company is now focusing on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections, while also implementing cost-cutting measures and exploring strategic alternatives.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Updates on Phase 2b Study for BX004

On November 25, 2025, BiomX Inc. announced updates regarding its Phase 2b study of BX004 for Cystic Fibrosis treatment, which faced a clinical hold by the FDA due to concerns over a third-party nebulizer device. The company is actively working with the manufacturer to resolve these issues and anticipates resuming U.S. enrollment once resolved and financing is secured. Additionally, an independent Data Monitoring Committee recommended continuing the study with an adjusted dosing regimen after a safety review, with topline results expected in the second quarter of 2026, contingent on financial resources.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.